4 ms·

It's "effective at preventing symptomatic disease". All the vaccines so far are 100% effective against "preventing severe disease" The last one (non-symptomat

It's "effective at preventing symptomatic disease". All the vaccines so far are 100% effective against "preventing severe disease" The last one (non-symptomatic), we don't really know, I don't think any studies have been done which regularly test everyone, at scale. Someone correct me if I'm wrong.

maxerickson 6y ago
There's some studies that have done regular testing, the vaccinations prevent infection. https://www.nejm.org/doi/full/10.1056/NEJMc2102153 https://www.nejm.org/doi/full/10.1056/NEJMc2102153 https://www.nejm.org/doi/full/10.1056/NEJMc2101927 https://www.nejm.org/doi/full/10.1056/NEJMc2101927 2 weeks after the second Pfizer dose, one of the medical centers had a positive test rate of 0.05% (not a typo, 0.05 percent).
- ehsankia 6y ago
  Those are great, though they are pretty early results. I think in both cases, they finished giving the 2nd dose around February, so we've only had around 1 month of data. I'm a little confused by the percentage though. Looking at the 2nd study, and ignoring 1-7 days after the second dose, there's still 8+7 people who got infected a week after the 2nd dose, out of ~5000 tested. How do they get to the 0.05% number? Also, if I understand correctly, the table says there's around 16,000 eligible, but only 4000-5000 were tested? Am I missing something?
  - maxerickson 6y ago
    I misinterpreted them is what it is. The 0.05% is 7/14990, so it's the infections identified in the vaccinated group and isn't about regular testing, it's just that the result may include cases that were identified by testing rather than being symptomatic.
ortusdux 6y ago
This is the key point that needs to be conveyed when the J&J 1-shot starts to be distributed. It has a 66-75% efficacy at preventing symptomatic disease, but 100% efficacy at preventing hospitalization. In situations where the 1-shot is ideal, patients being scared off by the lower efficacy rate could be an issue.
- ehsankia 6y ago
  Not only that, J&J is also doing a trial for 2nd shot, as well as some places such as UK ended up doing Pfizer/Moderna with one shot only with delayed 2nd shot (3-4 months later). So we'll see how that works out, there may be the possibility of getting a 2nd shot of J&J later down the line to increase your immunity. I believe Pfizer has even started doing 3rd shot boosters for very early phase 1-2 people from last year.
arisAlexis 6y ago
the 100% number probably doesn't include the P1,SA variants, no data on them. There is good probability that they become dominant so I'm waiting for the results on those.

maxerickson 6y ago

There's some studies that have done regular testing, the vaccinations prevent infection. https://www.nejm.org/doi/full/10.1056/NEJMc2102153 https://www.nejm.org/doi/full/10.1056/NEJMc2102153 https://www.nejm.org/doi/full/10.1056/NEJMc2101927 https://www.nejm.org/doi/full/10.1056/NEJMc2101927 2 weeks after the second Pfizer dose, one of the medical centers had a positive test rate of 0.05% (not a typo, 0.05 percent).

ehsankia 6y ago
Those are great, though they are pretty early results. I think in both cases, they finished giving the 2nd dose around February, so we've only had around 1 month of data. I'm a little confused by the percentage though. Looking at the 2nd study, and ignoring 1-7 days after the second dose, there's still 8+7 people who got infected a week after the 2nd dose, out of ~5000 tested. How do they get to the 0.05% number? Also, if I understand correctly, the table says there's around 16,000 eligible, but only 4000-5000 were tested? Am I missing something?
- maxerickson 6y ago
  I misinterpreted them is what it is. The 0.05% is 7/14990, so it's the infections identified in the vaccinated group and isn't about regular testing, it's just that the result may include cases that were identified by testing rather than being symptomatic.

ortusdux 6y ago

This is the key point that needs to be conveyed when the J&J 1-shot starts to be distributed. It has a 66-75% efficacy at preventing symptomatic disease, but 100% efficacy at preventing hospitalization. In situations where the 1-shot is ideal, patients being scared off by the lower efficacy rate could be an issue.

ehsankia 6y ago
Not only that, J&J is also doing a trial for 2nd shot, as well as some places such as UK ended up doing Pfizer/Moderna with one shot only with delayed 2nd shot (3-4 months later). So we'll see how that works out, there may be the possibility of getting a 2nd shot of J&J later down the line to increase your immunity. I believe Pfizer has even started doing 3rd shot boosters for very early phase 1-2 people from last year.

arisAlexis 6y ago

the 100% number probably doesn't include the P1,SA variants, no data on them. There is good probability that they become dominant so I'm waiting for the results on those.